Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SMS Pharmaceuticals Limited ( (IN:SMSPHARMA) ) has issued an update.
SMS Pharmaceuticals Limited reported that its board has approved the audited standalone and consolidated financial results for the fourth quarter and full year ended 31 March 2026, with the statutory auditors issuing an unmodified opinion. The board also recommended a final dividend of ₹0.40 per equity share for FY 2025-26, signalling continued shareholder returns, and confirmed that details of the annual general meeting and record dates will follow.
The company further approved shifting its registered office within Hyderabad to new premises in Kondapur, a move that may support operational expansion while remaining within the same city. In addition, the board appointed M/s. Annapragada & Co. as cost auditors and re-appointed M/s. Adusumilli & Associates as internal auditors for FY 2026-27, underscoring an ongoing focus on cost control, internal oversight and regulatory compliance.
More about SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited is an India-based pharmaceutical company engaged in manufacturing and supplying active pharmaceutical ingredients and related products. Headquartered in Hyderabad, Telangana, it serves both domestic and international markets from multiple facilities, focusing on regulated markets and compliance-driven operations within the broader healthcare and pharma industry.
Average Trading Volume: 14,680
Technical Sentiment Signal: Buy
Current Market Cap: 39.69B INR
See more insights into SMSPHARMA stock on TipRanks’ Stock Analysis page.